ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,051.09
0.00%
Dow Jones
43,828.06
-0.20%
US Dollar vs MXN
20.1304
0.00%
Brent Oil
74.135
0.00%
Bitcoin
101,559.16
0.10%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aclarion Inc (ACONW)

  7. Aclarion Inc (ACONW) Noticias

ACONW

Aclarion (ACONW)

Aclarion Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ACONW
FechaHoraFuenteTítuloSímboloCompañía
02/12/202405:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACONWAclarion Inc
27/11/202415:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACONWAclarion Inc
22/11/202415:03Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ACONWAclarion Inc
21/11/202407:00GlobeNewswire Inc.Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM FlashNASDAQ:ACONWAclarion Inc
14/11/202412:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACONWAclarion Inc
13/11/202414:06Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACONWAclarion Inc
08/11/202415:18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACONWAclarion Inc
04/11/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACONWAclarion Inc
04/11/202405:15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACONWAclarion Inc
25/10/202416:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ACONWAclarion Inc
15/10/202415:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACONWAclarion Inc
11/10/202415:36Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ACONWAclarion Inc
10/10/202406:00GlobeNewswire Inc.Aclarion to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:ACONWAclarion Inc
27/09/202405:57GlobeNewswire Inc.Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic ChangesNASDAQ:ACONWAclarion Inc
24/09/202415:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ACONWAclarion Inc
19/09/202416:02Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ACONWAclarion Inc
12/09/202405:57GlobeNewswire Inc.Aclarion Provides Corporate Update on Nociscan AI Technology MilestonesNASDAQ:ACONWAclarion Inc
10/09/202405:57GlobeNewswire Inc.Aclarion Announces Completion of First Nociscan Exams in LIFEHAB TrialNASDAQ:ACONWAclarion Inc
05/09/202405:57GlobeNewswire Inc.Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation MarketNASDAQ:ACONWAclarion Inc
29/08/202405:57GlobeNewswire Inc.Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New JerseyNASDAQ:ACONWAclarion Inc
21/08/202406:57GlobeNewswire Inc.Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment PlansNASDAQ:ACONWAclarion Inc
15/08/202408:48GlobeNewswire Inc.Aclarion to Present at August 20th Virtual Investor Summit Microcap EventNASDAQ:ACONWAclarion Inc
14/08/202407:08GlobeNewswire Inc.Aclarion Announces First Commercial Agreement in MichiganNASDAQ:ACONWAclarion Inc
13/08/202408:07GlobeNewswire Inc.Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UKNASDAQ:ACONWAclarion Inc
09/07/202406:00GlobeNewswire Inc.Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UKNASDAQ:ACONWAclarion Inc
26/06/202407:30GlobeNewswire Inc.Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UKNASDAQ:ACONWAclarion Inc
25/06/202407:30GlobeNewswire Inc.Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater LondonNASDAQ:ACONWAclarion Inc
25/04/202408:14GlobeNewswire Inc.Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back PainNASDAQ:ACONWAclarion Inc
04/03/202407:00GlobeNewswire Inc.Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar DiscsNASDAQ:ACONWAclarion Inc
27/02/202414:22GlobeNewswire Inc.Aclarion Announces Closing of $3.0 Million Public OfferingNASDAQ:ACONWAclarion Inc
 Showing the most relevant articles for your search:NASDAQ:ACONW

Su Consulta Reciente

FX
EURUSD
Euro vs US Dollar
CCOM
OILBRENT
Brent Oil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
FX
USDMXN
US Dollar vs MXN
COIN
XRPUSD
Ripple
COIN
DOGEUSD
Dogecoin
PM
XAUUSD
Gold vs US Dollar
CCOM
US30
US 30
NYSE
VZ
Verizon Communications
SPI
SP500
S&P 500
NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados